Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer
- PMID: 36041377
- DOI: 10.1016/j.suronc.2022.101823
Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer
Abstract
Background: Targeted axillary dissection, which combines sentinel lymph node biopsy with removal of the proven involved node noted during the staging process, has been shown to improve axillary staging and decrease false negative rates after neoadjuvant chemotherapy in patients with breast cancer.
Objective(s): The main goal of this study was to assess the ability to identify and remove the clipped node and the false negative rate of targeted axillary dissection.
Methods: We performed a prospective study among patients with biopsy-confirmed nodal metastases who received neoadjuvant chemotherapy. A clip was placed on the sample node prior systemic therapy. After neoadjuvant chemotherapy, all patients underwent sentinel lymph node biopsy (dual tracer), localization and excision of the clipped node and axillary lymph node dissection. The clipped node was preoperatively localized in all cases placing an iodine-125 seed guided by ultrasound. The pathology of the sentinel nodes and clipped node was compared with other nodes.
Results: A total of 455 patients with invasive breast cancer were studied. Of the 148 patients with NAC, 32 met the eligibility criteria and were enrolled in the study. Mean age at diagnosis was 52.3 years. Systematic lymphadenectomy was performed in all patients, with an average of 14.3 lymph nodes removed. Detection rate of the clipped node alone was 96.9%, and 100% for targeted axillary dissection. Ability of clipped node alone to predict nodal status showed a FNR of 10,5% while SLNB alone performed by dual tracer and targeted axillary dissection, showed FNRs of 5.3% and 5.0%, respectively. Sentinel lymph nodes matched clipped node in 23 patients (74.2%).
Conclusion (s): In node positive breast cancer patients, targeted axillary dissection is a reliably approach for axillary staging after neoadjuvant chemotherapy. The preoperative location of the clipped node is mandatory to increase the detection rate and optimize the results of the technique.
Keywords: Axillary lymph node dissection; Breast cancer; Clipped nodes; Neoadjuvant chemotherapy; Node positive; Targeted axillary dissection.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no conflicts of interest to declare.
Similar articles
-
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.J Clin Oncol. 2016 Apr 1;34(10):1072-8. doi: 10.1200/JCO.2015.64.0094. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811528 Free PMC article.
-
Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?Oncologist. 2020 Nov;25(11):e1621-e1627. doi: 10.1634/theoncologist.2020-0494. Epub 2020 Jul 7. Oncologist. 2020. PMID: 32537791 Free PMC article.
-
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.World J Surg Oncol. 2024 Jul 6;22(1):178. doi: 10.1186/s12957-024-03413-6. World J Surg Oncol. 2024. PMID: 38971793 Free PMC article.
-
Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.Cancer Med. 2022 Nov;11(22):4085-4103. doi: 10.1002/cam4.4769. Epub 2022 May 3. Cancer Med. 2022. PMID: 35502768 Free PMC article.
-
The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.Cir Esp (Engl Ed). 2020 Nov;98(9):510-515. doi: 10.1016/j.ciresp.2020.03.012. Epub 2020 May 6. Cir Esp (Engl Ed). 2020. PMID: 32386728 English, Spanish.
Cited by
-
Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: variation in type of marker and timing of placement.Br J Surg. 2024 Mar 2;111(3):znae071. doi: 10.1093/bjs/znae071. Br J Surg. 2024. PMID: 38531689 Free PMC article.
-
Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.Adv Exp Med Biol. 2024;1460:767-819. doi: 10.1007/978-3-031-63657-8_26. Adv Exp Med Biol. 2024. PMID: 39287872 Review.
-
Current axillary management of patients with early breast cancer and low-volume nodal disease undergoing primary surgery: results of a United Kingdom national practice survey.Breast Cancer Res Treat. 2024 Aug;206(3):465-471. doi: 10.1007/s10549-024-07328-4. Epub 2024 May 10. Breast Cancer Res Treat. 2024. PMID: 38724821 Free PMC article.
-
Evaluation of pathological complete response rates in breast cancer patients undergoing neoadjuvant therapy.Rev Bras Ginecol Obstet. 2025 Apr 30;47:e-rbgo13. doi: 10.61622/rbgo/2025rbgo13. eCollection 2025. Rev Bras Ginecol Obstet. 2025. PMID: 40406477 Free PMC article.
-
Axillary lymph node management strategies in cN + breast cancer patients after neoadjuvant chemotherapy.Clin Transl Oncol. 2025 Jul;27(7):2769-2777. doi: 10.1007/s12094-024-03817-6. Epub 2024 Dec 17. Clin Transl Oncol. 2025. PMID: 39688773 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous